708248-39-9Relevant academic research and scientific papers
Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors
Ball, Zachary T.,Cooper, Julian C.,Kasembeli, Moses M.,Kolosov, Mikhail I.,Krueger, Michael J.,Liu, Wei,Mangubat-Medina, Alicia E.,Minus, Matthew B.,Munoz, Jaime O.,Redell, Michele S.,Stevens, Alexandra M.,Tweardy, David J.,Wang, Haopei
, p. 3288 - 3296 (2020)
Recurrence and drug resistance are major challenges in the treatment of acute myeloid leukemia (AML) that spur efforts to identify new clinical targets and active agents. STAT3 has emerged as a potential target in resistant AML, but inhibiting STAT3 function has proven challenging. This paper describes synthetic studies and biological assays for a naphthalene sulfonamide inhibitor class of molecules that inhibit G-CSF-induced STAT3 phosphorylation in cellulo and induce apoptosis in AML cells. We describe two different approaches to inhibitor design: first, variation of substituents on the naphthalene sulfonamide core allows improvements in anti-STAT activity and creates a more thorough understanding of anti-STAT SAR. Second, a novel approach involving hybrid sulfonamide-rhodium(ii) conjugates tests our ability to use cooperative organic-inorganic binding for drug development, and to use SAR studies to inform metal conjugate design. Both approaches have produced compounds with improved binding potency.In vivoand in cellulo experiments further demonstrate that these approaches can also lead to improved activity in living cells, and that compound3aaslows disease progression in a xenograft model of AML.
